Documentos de Xavier D. | REDI

Regresar

Mostrando 3 resultados de: 3

Filtros aplicados

Palabras Claves: "Cardiovascular disease"

Subtipo de publicación

Publisher

Diabetes, Obesity and Metabolism(1)

European Heart Journal(1)

European Heart Journal - Quality of Care and Clinical Outcomes(1)

Área temáticas

Medicina y salud(3)

Enfermedades(2)

Farmacología y terapéutica(2)

Fisiología humana(1)

Problemas sociales y servicios a grupos(1)

Área de conocimiento

Enfermedad cardiovascular(2)

Medicina interna(2)

Farmacología(1)

Año de Publicación

Origen

Palabras Claves

Primary Prevention(2)

Clinical trial(1)

GLP-1 receptor agonist(1)

antidiabetic drug(1)

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

Abstract: The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human gluca

Palabras claves:

antidiabetic drug, Cardiovascular disease, Clinical trial, diabetes complications, GLP-1 receptor agonist

Atisso C.M., Avezum A.J., Basile J.N., Cardona-Munoz E.G., Chung N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., DIaz R., Franek E., Gerstein H.C., Hâncu N., Hanefeld M., Holt S., Jansky P., Keltai M., Lakshmanan M., Lanas F., Leiter L.A., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.

Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Abstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) e

Palabras claves:

Cardiovascular disease, Primary Prevention, statins

Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.

The cost implications of a polypill for primary prevention in the TIPS-3 trial

Abstract: Aims The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing choles

Palabras claves:

Cardiovascular disease, cost analysis, Polypill, Primary Prevention

Dans A.L., Gamra H., Gao P., Joseph P.G., Lamy A., Pais P., PATRICIO LOPEZ -JARAMILLO, Santoso A., Talukder S.H., Tong W., Walli-Attaei M., Xavier D., Yusuf S.